Development and validation of a quantitative, High-throughput, Fluorescent-based bioassay to detect schistosoma viability

PLoS Neglected Tropical Diseases

Volumn 4, Issue 7, 2010, Pages

  Peak, Emily ^a   Chalmers, Iain W ^a   Hoffmann, Karl F ^a  

^a ABERYSTWYTH UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AURANOFIN; BEPRIDIL; CARBIDOPA; CHLORPROMAZINE; CICLOPIROX; ETHINYLESTRADIOL; FLUCYTOSINE; FLUORESCEIN DIACETATE; FLUOXETINE; GAMBOGIC ACID; MICONAZOLE NITRATE; NICLOSAMIDE; PRAZIQUANTEL; PROPIDIUM IODIDE; RESCINNAMINE; SALINOMYCIN; VINBLASTINE; ANTHELMINTIC AGENT; FLUORESCENT DYE;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MICROSCOPY; MICROTITER PLATE ASSAY; NONHUMAN; PARASITE CULTIVATION; PARASITE IDENTIFICATION; PARASITE SURVIVAL; PARASITE VIABILITY; PHENOTYPE; QUANTITATIVE ANALYSIS; SCHISTOSOMA; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHISTOSOMULUM; SENSITIVITY ANALYSIS; VALIDATION PROCESS; ANIMAL; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; MICROBIAL VIABILITY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANIMALS; ANTHELMINTICS; DRUG EVALUATION, PRECLINICAL; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL VIABILITY; SCHISTOSOMA; SENSITIVITY AND SPECIFICITY;

EID: 77957914128     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000759     Document Type: Article

References (24)

1. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. J Lancet 365: 1561-1569.
2. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19: 509-515.
3. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, et al. (2009) The genome of the blood fluke Schistosoma mansoni. Nature 460: 352-358.
4. Brindley PJ, Pearce EJ (2007) Genetic manipulation of schistosomes. Int J for Parasitol 37: 465-473.
5. Hokke CH, Fitzpatrick JM, Hoffmann KF (2007) Integrating transcriptome, proteome and glycome analyses of Schistosoma biology. Trends Parasitol 23: 165-174.
6. Colley DG, Secor WE (2007) A schistosomiasis research agenda. PLoS Negl Trop Dis 1: e32.
7. Keiser J (2009) In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 137: 589-603.
8. Hoffmann KF, James SL, Cheever AW, Wynn TA (1999) Studies with double cytokine-deficient mice reveal that highly polarized Th1-and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni. J Immunol 163: 927.
9. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, et al. (2007) Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target. PLoS Medicine 4: e206.
10. Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, et al. (2009) Drug Discovery for Schistosomiasis: Hit and Lead Compounds Identified in a Library of Known Drugs by Medium-Throughput Phenotypic Screening. PLoS Negl Trop Dis 3: e478.
11. Gold D (1997) Assessment of the viability of Schistosoma mansoni schistosomula by comparative uptake of various vital dyes. Parasitol Res 83: 163-169.
12. Jones K, Senft J (1985) An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. J Histochem Cytochem 33: 77-79.
13. Colley DG, Wikel SK (1974) Schistosoma mansoni: simplified method for the production of schistosomules. Exp Parasitol 35: 44-51.
14. Lazdins JK, Stein MJ, David JR, Sher A (1982) Schistosoma mansoni: rapid isolation and purification of schistosomula of different developmental stages by centrifugation on discontinuous density gradients of Percoll. Exp Parasitol 53: 39.
15. Clarke JM, Gillings MR, Atlavilla N, Beattie AJ (2001) Potential problems with fluorescein diacetate assays of cell viability when testing natural products of antimicrobial activity. J Microbiol Methods 46: 261-267.
16. King CH, Dangerfield-Cha M (2008) The unacknowledged impact of chronic schistosomiasis. Chronic Illn 4: 65.
17. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, et al. (2009) Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136: 1825-1835.
18. Zhou Y, Zheng H, Chen Y, Zhang L, Wang K, et al. (2009) The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 460: 345-351.
19. Tanowitz HB, Weiss LM, Wittner M (1993) Diagnosis and treatment of intestinal helminths. I. Common intestinal cestodes. Gastroenterologist 1: 265-273.
20. Harder A (2002) Chemotherapeutic approaches to trematodes (except schistosomes) and cestodes: current level of knowledge and outlook. Parasitol Res 88: 587-590.
21. Coura-Filho P, Mendes NM, Souza CP, Pereira JP (1992) The prolonged use of niclosamide as a molluscicide for the control of Schistosoma mansoni. Rev Inst Med Trop São Paulo 34: 427-431.
22. Fitzpatrick JM, Peak E, Perally S, Chalmers IW, Barrett J, et al. (2009) Antischistosomal Intervention Targets Identified by Lifecycle Transcriptomic Analyses. PLoS Negl Trop Dis 3: e543.
23. Curwen RS, Ashton PD, Johnston DA, Wilson RA (2004) The Schistosoma mansoni soluble proteome: a comparison across four life-cycle stages. Mol Biochem Parasitol 138: 57-66.
24. Knudsen GM, Medzihradszky KF, Lim KC, Hansell E, McKerrow JH (2005) Proteomic analysis of Schistosoma mansoni cercarial secretions. Mol Cell Proteomics 4: 1862-1875.